DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Ambrisentan

Ambrisentan

  • Endothelin System and Therapeutic Application of Endothelin Receptor

    Endothelin System and Therapeutic Application of Endothelin Receptor

  • 4 Tier)

    4 Tier)

  • Summary of Appeals & Independent Review Organization

    Summary of Appeals & Independent Review Organization

  • Ambrisentan (Letairis®) Issued by PHA’S Scientific Leadership Council Information Is Based on the United States Food and Drug Administration Drug Labeling

    Ambrisentan (Letairis®) Issued by PHA’S Scientific Leadership Council Information Is Based on the United States Food and Drug Administration Drug Labeling

  • Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log

    Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log

  • Therapeutic Classes Additions (Preferred) Removals (Non-Preferred)

    Therapeutic Classes Additions (Preferred) Removals (Non-Preferred)

  • 84 November 2008 Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

    84 November 2008 Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

  • List of Formulary Drug Removals

    List of Formulary Drug Removals

  • Pennsylvania Department of Human Services Statewide Preferred Drug List (PDL)*

    Pennsylvania Department of Human Services Statewide Preferred Drug List (PDL)*

  • Ambrisentan (Letairis and Opsumit)

    Ambrisentan (Letairis and Opsumit)

  • Wednesday, April 8, 2015 4 P.M

    Wednesday, April 8, 2015 4 P.M

  • 1 Continue Until the Day Before the Operation, but Hold on Day of Surgery

    1 Continue Until the Day Before the Operation, but Hold on Day of Surgery

  • Volibris, INN-Ambrisentan

    Volibris, INN-Ambrisentan

  • Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S

    Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S

  • Advanced Control Specialty Formulary® Is a Guide Within Select Therapeutic Categories for Clients, Plan Members and Health Care Providers

    Advanced Control Specialty Formulary® Is a Guide Within Select Therapeutic Categories for Clients, Plan Members and Health Care Providers

  • Therapeutic Drug Class

    Therapeutic Drug Class

  • E-Binder March 2021

    E-Binder March 2021

  • Distinct ETA Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis

    Distinct ETA Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis

Top View
  • 2020 Complete Drug List (Formulary)
  • NEW--Npf-MASTER LIST.Xlsx
  • Brand Generic Guide
  • Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
  • Medicaid Health Plan Common Formulary
  • Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health
  • Pulmonary Arterial Hypertension: Role of Ambrisentan
  • FEP 5 Tier Rx Drug Formulary (607) Standard Option
  • Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
  • Drug Coverage Guidelines – Oxford Clinical Policy
  • Endothelin Receptor Antagonists (Eras) Annual Review Date: Tracleer (Bosentan) 1/21/2021 Letairis (Ambrisentan) Opsumit (Macitentan) Last Revised Date: 2/18/2021
  • SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
  • Read the Notice
  • Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
  • Liver Toxicity of Sitaxentan in Pulmonary Arterial Hypertension
  • 2021 Aetna Specialty Drug List
  • January 13, 2020
  • Preferred Brand Drugs with Non-Preferred Generic Drugs PDL


© 2024 Docslib.org    Feedback